ArticleCell death & disease2026
Tumor-derived PCSK9-enriched exosomes reprogram adipocytes to drive metabolic dysregulation and immune evasion in triple-negative breast cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is characterized by aggressive behaviors, limited treatment options, and poor prognosis. Adipocytes, the predominant cellular component in the tumor microenvironment (TME) of breast cancer, interact bidirectionally with tumor cells, influencing tumor progression and immune evasion. Understanding the interactions between TNBC cells and adipocytes within TME is crucial for identifying new therapeutic targets. We employed murine models and co-culture systems to investigate the effects of adipocyte-TNBC cell interactions on lipid metabolism, signaling pathways, and immune evasion mechanisms. Our findings revealed that TNBC cells utilized PCSK9-enriched exosome transfer to induce the formation of cancer-associated adipocytes (CAAs) from adipocytes. These CAAs, characterized by altered lipid content and a pro-inflammatory secretory profile, contributed to a tumor-promoting environment. Additionally, CAAs enhanced the immune evasion properties of TNBC by modifying the metabolic pathways of tumor cells. In depth, CAAs induced fatty acid oxidation (FAO) in TNBC cells, which facilitated G3BP1-induced stabilization of PCSK9 and promoted OPTN-mediated autophagic degradation of the co-stimulatory molecules CD80 and CD86, which are essential for T cell activation. Our study identifies PCSK9 as a central mediator in the bidirectional interactions between TNBC cells and adipocytes, influencing tumor progression and immune evasion. These insights suggest that targeting the PCSK9 pathway could provide new therapeutic opportunities for TNBC, potentially transforming treatment approaches and improving patient outcomes. Further investigation into the mechanisms by which PCSK9 regulates these processes may yield novel combination strategies to enhance the efficacy of immunotherapy in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.